AR105774A1 - Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico - Google Patents

Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico

Info

Publication number
AR105774A1
AR105774A1 ARP160102552A ARP160102552A AR105774A1 AR 105774 A1 AR105774 A1 AR 105774A1 AR P160102552 A ARP160102552 A AR P160102552A AR P160102552 A ARP160102552 A AR P160102552A AR 105774 A1 AR105774 A1 AR 105774A1
Authority
AR
Argentina
Prior art keywords
formula
naftiridine
etoxi
metoxyphenyl
ciano
Prior art date
Application number
ARP160102552A
Other languages
English (en)
Inventor
Dr Platzek Johannes
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR105774A1 publication Critical patent/AR105774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Reivindicación 1: Un procedimiento para preparar el compuesto de la fórmula (1) caracterizado porque el compuesto racémico de la fórmula (2) se separa en sus enantiómeros y el compuesto de la fórmula (2) se produce haciendo reaccionar el compuesto de la fórmula (3) con el ortoéster de fórmula (4) donde R puede representar H o metilo y el compuesto de la fórmula (5), se produce, haciendo reaccionar los compuestos de la fórmula (6 a,b) con el compuesto de la fórmula (7) y el compuesto de la fórmula (6 a,b) se produce haciendo reaccionar el compuesto de la fórmula (8) con el compuesto de la fórmula (9).
ARP160102552A 2015-08-21 2016-08-19 Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico AR105774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15182043 2015-08-21

Publications (1)

Publication Number Publication Date
AR105774A1 true AR105774A1 (es) 2017-11-08

Family

ID=53938271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102552A AR105774A1 (es) 2015-08-21 2016-08-19 Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico

Country Status (31)

Country Link
US (2) US10336749B2 (es)
EP (1) EP3337800B1 (es)
JP (1) JP6824247B2 (es)
KR (1) KR20180041138A (es)
CN (1) CN107849043B (es)
AR (1) AR105774A1 (es)
AU (1) AU2016312904C1 (es)
CA (1) CA2995905A1 (es)
CL (1) CL2018000427A1 (es)
CO (1) CO2018001466A2 (es)
DK (1) DK3337800T3 (es)
ES (1) ES2739904T3 (es)
HK (1) HK1251565A1 (es)
HR (1) HRP20191431T1 (es)
HU (1) HUE044574T2 (es)
IL (1) IL257371B (es)
JO (1) JOP20160186B1 (es)
LT (1) LT3337800T (es)
MX (1) MX367960B (es)
MY (1) MY195226A (es)
PE (1) PE20180554A1 (es)
PL (1) PL3337800T3 (es)
PT (1) PT3337800T (es)
RS (1) RS59055B1 (es)
RU (1) RU2743429C2 (es)
SG (1) SG11201801110TA (es)
SI (1) SI3337800T1 (es)
TW (1) TWI725045B (es)
UY (1) UY36864A (es)
WO (1) WO2017032673A1 (es)
ZA (1) ZA201801859B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317265B (zh) * 2018-03-28 2023-03-10 江苏豪森药业集团有限公司 比伐芦定晶型a及其制备方法
EP3560922A1 (de) * 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
EP3566704A1 (en) * 2018-05-11 2019-11-13 Bayer Aktiengesellschaft The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases
BR112022005605A2 (pt) * 2019-10-17 2022-07-19 Bayer Ag Processo para preparar aciloximetil ésteres de ácido (4s)-(4-ciano-2-metoxifenil)-5-etóxi-2,8-dimetil-1,4-di-hidro-1,6-naftiridina-3-carboxílico
CN114524812A (zh) * 2022-03-18 2022-05-24 湖南凯铂生物药业有限公司 1,4-二氢-1,6-萘啶化合物的晶型制备以及合成方法
WO2023205164A1 (en) 2022-04-18 2023-10-26 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431303A1 (de) * 1984-08-25 1986-02-27 Goedecke Ag 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
US6350762B1 (en) * 1997-12-22 2002-02-26 Ajinomoto Co., Inc. Dihydropyridine derivative
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2007007018A1 (en) 2005-07-12 2007-01-18 Glaxo Group Limited Piperazine heteroaryl derivates as gpr38 agonists
DE102006026583A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
PT3174875T (pt) 2014-08-01 2020-11-05 Bayer Pharma AG Processo para a produção de (4s)-4-(4-ciano-2- metoxifenil)-5-etoxi-2,8-dimetil-1,4-di-hidro-1,6- naftiridino-3-carboxamida e a sua purificação para a utilização como princípio ativo farmacêutico

Also Published As

Publication number Publication date
CN107849043A (zh) 2018-03-27
KR20180041138A (ko) 2018-04-23
HRP20191431T1 (hr) 2019-11-01
MY195226A (en) 2023-01-11
AU2016312904B2 (en) 2020-12-10
IL257371B (en) 2021-04-29
HUE044574T2 (hu) 2019-11-28
MX367960B (es) 2019-09-12
UY36864A (es) 2017-03-31
TW201722944A (zh) 2017-07-01
EP3337800B1 (de) 2019-06-12
CN107849043B (zh) 2020-10-16
LT3337800T (lt) 2019-08-12
AU2016312904C1 (en) 2021-05-27
MX2018002027A (es) 2018-06-15
JOP20160186B1 (ar) 2021-08-17
RU2018109761A (ru) 2019-09-23
CA2995905A1 (en) 2017-03-02
PL3337800T3 (pl) 2019-10-31
PE20180554A1 (es) 2018-04-02
WO2017032673A1 (de) 2017-03-02
US10336749B2 (en) 2019-07-02
ES2739904T3 (es) 2020-02-04
RU2018109761A3 (es) 2020-01-21
AU2016312904B9 (en) 2020-12-24
IL257371A (en) 2018-04-30
US20180244670A1 (en) 2018-08-30
ZA201801859B (en) 2019-11-27
HK1251565A1 (zh) 2019-02-01
RU2743429C2 (ru) 2021-02-18
JP6824247B2 (ja) 2021-02-03
RS59055B1 (sr) 2019-08-30
EP3337800A1 (de) 2018-06-27
SG11201801110TA (en) 2018-03-28
PT3337800T (pt) 2019-08-05
CO2018001466A2 (es) 2018-02-28
TWI725045B (zh) 2021-04-21
DK3337800T3 (da) 2019-08-19
AU2016312904A1 (en) 2018-03-08
USRE49826E1 (en) 2024-02-06
JP2018523699A (ja) 2018-08-23
CL2018000427A1 (es) 2018-07-20
SI3337800T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005722A (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PH12016501440A1 (en) Novel heterocyclic compounds
UY36734A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2017000886A2 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificación para su uso como principio activo farmacéutico
CO2017001884A2 (es) Polimorfos de selinexor
NZ726356A (en) Processes for preparing antiviral compounds
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA201791304A1 (ru) Производные изохинолина для лечения вич
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
EP3404032A3 (en) Process for making benzoxazepin compounds
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
CO2018002364A2 (es) Una novedosa forma de isoxadifeno-etilo, un proceso para su preparación y uso de la misma
BR112016022437A2 (pt) Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
PE20142433A1 (es) Proceso para la elaboracion de undecapeptidos ciclicos